Cargando…
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
Transthyretin hereditary amyloid polyneuropathy, also traditionally known as transthyretin familial amyloid polyneuropathy (ATTR-FAP), is a rare, relentless, fatal hereditary disorder. Tafamidis, an oral, non-NSAID, highly specific transthyretin stabilizer, demonstrated safety and efficacy in slowin...
Autores principales: | Waddington Cruz, Márcia, Amass, Leslie, Keohane, Denis, Schwartz, Jeffrey, Li, Huihua, Gundapaneni, Balarama |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359776/ https://www.ncbi.nlm.nih.gov/pubmed/27494299 http://dx.doi.org/10.1080/13506129.2016.1207163 |
Ejemplares similares
-
Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
por: Waddington-Cruz, Marcia, et al.
Publicado: (2015) -
Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
por: Amass, Leslie, et al.
Publicado: (2018) -
Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
por: Keohane, Denis, et al.
Publicado: (2015) -
Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy
por: Gundapaneni, B. K., et al.
Publicado: (2017) -
Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
por: Sultan, Marla B, et al.
Publicado: (2017)